Quick answer: common BPC‑157 dosage claims (not medical advice)
There is no standard, approved human dose. Across forums, blogs and clinic marketing, people most often cite:
- Injectable BPC‑157: 200–500 mcg per day (once daily or split twice daily) for 2–4 weeks; some extend to 6–12 weeks with breaks.
- Oral capsules: 250–500 mcg 1–2 times daily for 4–8 weeks (bioavailability and efficacy are debated).
- Topical preparations: roughly 200–500 mcg per application to a local area 1–2 times daily.
Important: BPC‑157 is unapproved in Australia; product quality and concentration vary; athletes face anti‑doping risk. Speak with a qualified healthcare professional before any use.
Common forms and strengths people encounter
- Injectable powder vials: 2 mg, 5 mg or 10 mg lyophilised powder to reconstitute with bacteriostatic water.
- Oral capsules: often 250 mcg or 500 mcg per capsule, compounded. Evidence in humans is limited.
- Topical gels/creams: concentrations vary widely (for example, 0.1–0.5 mg/mL or stated mcg per pump).
Because these are unapproved products, labelled strength may not match content. Quality control is a major safety variable.
Example protocols people post online (for education only)
These reflect commonly shared patterns, not recommendations. Stop if adverse effects occur and seek medical advice.
1) Tendon/ligament injury protocol claims
- 250 mcg subcutaneous injection twice daily near (not into) the affected area for 2–4 weeks, then 250 mcg once daily for 2 more weeks.
- Alternative: 400–500 mcg once daily for 10–20 days, then reassess. Some rotate between bilateral sides if relevant.
Notes: “Site” injections for peptides are debated; sterile technique and general injection know‑how are essential.
2) Gut support protocol claims
- Oral capsules 250–500 mcg twice daily, often before meals, for 4–8 weeks.
Notes: Human evidence is limited; oral bioavailability remains uncertain.
3) Topical application claims
- 200–500 mcg per application to a local area 1–2 times daily for 1–2 weeks.
Notes: Watch for irritation or infection; topical sterility and excipient quality vary.
Step‑by‑step: reconstitution and syringe math (to avoid unit mistakes)
- Wash hands and clean the vial rubber stopper with an alcohol swab. Use bacteriostatic water unless directed otherwise.
- Insert the needle, let the water run slowly down the inside glass to reduce foaming. Do not shake; gently swirl to dissolve.
- Label the vial with concentration and the date you mixed it. Refrigerate at 2–8°C. Many users discard after 2–4 weeks post‑mix (product instructions vary).
U‑100 insulin syringe conversion (1 unit = 0.01 mL)
Example A: 5 mg vial + 2 mL bacteriostatic water
- Concentration = 5 mg / 2 mL = 2.5 mg/mL = 2500 mcg/mL
- 200 mcg dose = 200 ÷ 2500 mL = 0.08 mL = 8 “units” on a U‑100 insulin syringe
- 250 mcg dose = 0.10 mL = 10 units; 500 mcg dose = 0.20 mL = 20 units
Example B: 5 mg vial + 5 mL bacteriostatic water
- Concentration = 1 mg/mL = 1000 mcg/mL
- 200 mcg dose = 0.20 mL = 20 units; 250 mcg = 0.25 mL = 25 units; 500 mcg = 0.50 mL = 50 units
Example C: 2 mg vial + 2 mL bacteriostatic water
- Concentration = 1 mg/mL = 1000 mcg/mL (same math as Example B)
Common pitfalls: mixing up mg vs mcg; confusing mL with “units”; not writing the concentration on the vial after mixing.
Timing, administration and cycling ideas people discuss
- Timing: many inject once in the morning or split morning/evening; oral users often take before meals.
- Duration: 2–4 weeks is commonly cited for acute soft‑tissue issues; some extend to 6–12 weeks with breaks.
- Cycling: 2–4 weeks on, 1–2 weeks off is often mentioned online to “assess response.”
- Stacks: often paired with TB‑500/Thymosin Beta 4 in forum posts; stacking increases uncertainty and risk.
Safety basics, side effects and red flags
- There are no large, high‑quality human trials establishing safety, efficacy, or dosing standards for BPC‑157.
- Reported reactions include injection site irritation, headache, dizziness, digestive upset and sleep changes. Unknown long‑term risks.
- Avoid if pregnant, breastfeeding, under 18, or with active cancer, unless advised by a specialist with informed consent.
If you suspect an overdose or severe reaction, call the Australian Poisons Information Centre on 13 11 26 or visit poisonsinfo.nsw.gov.au. In an emergency, call 000.
Legal status and anti‑doping warnings (Australia)
- BPC‑157 is generally considered an unapproved therapeutic good in Australia. Access, compounding and advertising are tightly regulated.
- Importing or buying from overseas websites can breach TGA and Customs rules, and products may be seized.
- Athletes: BPC‑157 falls under WADA’s S0 “Non‑approved Substances” and is prohibited at all times.
Authoritative resources:
- WADA Prohibited List (S0 non‑approved substances): wada-ama.org/en/prohibited-list
- TGA: Unapproved therapeutic goods – access overview: tga.gov.au/basics/unapproved-therapeutic-goods
- TGA: Personal importation scheme: tga.gov.au/resources/topic-pages/personal-importation-scheme
For local context, see: Is BPC‑157 legal in Australia?, Personal Importation Scheme explained, Unapproved peptides in Australia, Compounded peptides: rules and scrutiny.
What the evidence actually says (short version)
- Most support for BPC‑157 comes from animal or in‑vitro studies on tendon, ligament, muscle, nerve and gut models.
- Robust human clinical data are lacking; dosing used in animals does not directly translate to humans.
- Because there is no approved human indication, there is no “official” dose.
See peer‑reviewed overviews and regulatory commentary for context: PubMed, TGA, WADA.
Frequently asked questions (BPC‑157 dosage)
Is there a medically accepted BPC‑157 dose?
No. There is no approved indication or standard human dose. Ranges shared online are anecdotal.
What dose do people most often cite for injections?
Common claims are 200–500 mcg daily, sometimes split twice daily, typically for 2–4 weeks.
How do I convert mcg to insulin syringe units?
On U‑100 syringes, 1 unit = 0.01 mL. After you calculate mcg/mL from your reconstitution, divide the target mcg by mcg/mL to get mL, then multiply by 100 for units. Examples are shown above.
Can I inject “at the injury site”?
People discuss subcutaneous injections near an injury, not into it. Site injection practice is debated and carries risks. Seek clinical guidance.
Is BPC‑157 banned in sport?
Yes. It is prohibited under WADA’s S0 “Non‑approved Substances.” Athletes should not use it.
Where can I learn the basics of safe injection technique?
See our Peptide Injection Guide and consult a qualified clinician.
What if I experience side effects?
Stop use and seek medical advice. For urgent concerns, call the Poisons Information Centre on 13 11 26. In an emergency, call 000.
Get help: ask a dosing, safety or access question
Send a confidential message. We’ll point you to evidence, legal considerations in Australia, and options to speak with qualified clinicians.
Related BPC‑157 resources
General Peptide Dosage Guide Are Peptides Legal in Australia?